Zevalin Related Published Studies
Well-designed clinical trials related to Zevalin (Ibritumomab Tiuxetan)
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. [2007.09]
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. [2007.05.01]
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. [2004.09]
Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy. [2003.04]
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. [2002.05.15]
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. [2001.07]
Well-designed clinical trials possibly related to Zevalin (Ibritumomab Tiuxetan)
4. Antibody therapy for malignant lymphoma. [2007]
Other research related to Zevalin (Ibritumomab Tiuxetan)
Phase III Trial of Consolidation Therapy With Yttrium-90-Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma. [2008.10.14]
Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan. [2008.10]
Relative biologic effects of low-dose-rate alpha-emitting 227Th-rituximab and beta-emitting 90Y-tiuexetan-ibritumomab versus external beam X-radiation. [2008.09.01]
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study. [2008.09]
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in primary cutaneous B-cell lymphomas: first results of a prospective, monocentre study. [2008.07.25]
Extravasation of yttrium-90 ibritumomab tiuxetan: a case study. [2008.04]
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). [2008.04]
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. [2008.04]
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). [2008.03.12]
B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience. [2008.03]
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma. [2008.02.15]
Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. [2008.02]
Comparison between 2D and 3D dosimetry protocols in 90Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma. [2008.02]
Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma. [2008.02]
Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma. [2008.02]
Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. [2008.01.01]
Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma. [2008.01]
Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma. [2007.12.01]
In-111 ibritumomab scintigraphy (planar and SPECT) and FDG PET/CT before Y-90 ibritumomab treatment in a patient with mantle cell lymphoma. [2007.12]
Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan. [2007.12]
Current status and future perspectives for yttrium-90 ((90)Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma. [2007.12]
High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. [2007.11]
Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. [2007.11]
Yttrium 90 ibritumomab tiuxetan (Zevalin): a new bullet in the fight against malignant lymphoma? [2007.11]
High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas. [2007.11]
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. [2007.10]
Imaging of the distribution of (90)y-ibritumomab tiuxetan in bone marrow and comparison with pathology. [2007.10]
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. [2007.09.20]
A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study. [2007.09.15]
Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. [2007.09]
Use of radioimmunotherapy in stem cell transplantation and posttransplantation: focus on yttrium 90 ibritumomab tiuxetan. [2007.09]
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. [2007.07.01]
Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide. [2007.07]
Relapsed follicular lymphoma sequentially treated with rituximab and 90Y-ibritumomab tiuxetan. Case report. [2007.06]
Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. [2007.05.28]
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. [2007.04]
EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). [2007.04]
Phase I trial of (90)Y-ibritumomab tiuxetan in patients with relapsed B-cell non-Hodgkin's lymphoma following high-dose chemotherapy and autologous stem cell transplantation. [2007.04]
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. [2007.02]
Antibody therapy in non-Hodgkin's lymphoma: the role of rituximab, 90Y-ibritumomab tiuxetan, and alemtuzumab. [2007]
Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. [2006.11]
Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. [2006.08.15]
Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. [2006.07.15]
[90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab] [2006.07]
Ibritumomab tiuxetan for non-Hodgkin's lymphoma. [2006.06]
Yttrium 90 ibritumomab tiuxetan in lymphoma. [2006.06]
Extravazation of therapeutic yttrium-90-ibritumomab tiuxetan (zevalin): a case report. [2006.04]
Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. [2006.04]
Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. [2006.01]
Pretargeted radioimmunotherapy. [2006]
[Radiation exposure in (90)Y-Zevalin therapy: results of a prospective multicentre trial] [2006]
Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma. [2005.12]
The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. [2005.11]
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. [2005.10.15]
Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. [2005.10.01]
FDG PET CT assessment of treatment response after yttrium-90 ibritumomab tiuxetan radioimmunotherapy. [2005.08]
Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma. [2005.05]
90Y-ibritumomab tiuxetan: rationale for patient selection in the treatment of indolent non-Hodgkin's lymphoma. [2005.02]
Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma. [2005.02]
The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma. [2005]
[Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives] [2005]
Radioimmunotherapy in non-Hodgkin's lymphoma: focus on 90Y-ibritumomab tiuxetan (Zevalin). [2004.12]
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. [2004.12]
Ongoing trials with yttrium 90-labeled ibritumomab tiuxetan in patients with non-Hodgkin's lymphoma. [2004.10]
Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. [2004.10]
Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. [2004.10]
Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond. [2004.10]
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia. [2004.08]
90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma. [2004.08]
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. [2004.06.15]
Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. [2004.05.15]
Accurate dose calibrator activity measurement of 90Y-ibritumomab tiuxetan. [2004.03]
Educating patients about radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). [2004.02]
Radiation safety with yttrium 90 ibritumomab tiuxetan (Zevalin) radioimmunotherapy. [2004.02]
Efficacy and safety of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). [2004.02]
Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. [2004.02]
Radiation safety guidelines for radioimmunotherapy with yttrium 90 ibritumomab tiuxetan. [2004.02]
Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin). [2004.01]
Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). [2004.01]
Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). [2004.01]
Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). [2004.01]
Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician. [2004.01]
Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen. [2004]
Practical considerations and radiation safety in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin). [2003.12]
Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin). [2003.12]
Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. [2003.12]
Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). [2003.12]
Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma. [2003.08]
Radiation safety considerations with therapeutic 90Y Zevalin. [2003.08]
Use of ibritumomab tiuxetan anti-CD20 radioimmunotherapy in a non-Hodgkin's lymphoma patient previously treated with a yttrium-90-labeled anti-CD22 monoclonal antibody. [2003.06]
90Y-ibritumomab tiuxetan in the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. [2003.06]
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma. [2003.04.01]
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. [2003.03]
Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy. [2003]
|
